Ibrutinib and Rituximab vs Fludarabine, Cyclophosphamide, and Rituximab for Previously Untreated CLL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
Lancet Oncol 2023 May 01;24(5)535-552, P Hillmen, A Pitchford, A Bloor, A Broom, M Young, B Kennedy, R Walewska, M Furtado, G Preston, JR Neilson, N Pemberton, G Sidra, N Morley, K Cwynarski, A Schuh, F Forconi, N Elmusharaf, S Paneesha, CP Fox, DR Howard, A Hockaday, JM Brown, DA Cairns, S Jackson, N Greatorex, N Webster, J Shingles, S Dalal, PEM Patten, D Allsup, A Rawstron, T MunirFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.